Main Article Content
Background: The prevalence of Hepatitis C virus in Egypt reaches 15%, which is considered the highest in the world. Genotype 4 represents 93 % of Egyptian HCV infections. Non-Hodgkin lymphoma (NHL) is the 5th most common cancer in Egypt. The association between HCV infection and occurrence of B-cell NHL is well known while data are scarce in Eastern countries. Objectives: We aimed to evaluate the prevalence of HCV infection among patients with B-cell NHL and the clinical characteristics of HCV associated B-cell NHL in Delta region (Mansoura-Egypt). Methods: Between March 2012 and March 2013, 110 adult patients newly diagnosed with B-cell NHL were enrolled in the current study. This study was carried out at Oncology Center, Mansoura University. Study subjects provided serum for HCV testing and for HCV RNA. Results: The prevalence of HCV infection among these patients was 61% (67/110 patients) which is the highest reported value in literature. Among them, 80% (32/40 tested patients) presented with viremia. Contrasting with the histological distribution previously described in Northern regions, the majority of HCV associated lymphomas were DLBCLs (72 %) followed by SLL/CLL (13 %), follicular lymphomas (7.5%) and 7.5% of marginal zone lymphomas. In conclusion: B-cell lymphomas are highly associated with HCV infection in Egypt. Further developments are needed to give access to antiviral treatment for those patients in Delta region.
Downloads month by month
2. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol. 1999;31:3–8.
3. Turner NC, Dusheiko G, Jones A. Hepatitis C and B-cell lymphoma. Ann Oncol. 2003;14:1341–5.
4. Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:130–44.
5. Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol. 2007;60:1378–83.
6. Taborelli M, Polesel J, Montella M, Libra M, Tedeschi R, Battiston M, et al. Hepatitis B and C viruses and risk of non-Hodgkin lymphoma : a case-control study in Italy. Infect Agent Cancer. 2016;1–6.
7. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.
8. Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010–7.
9. Nieters A, Kallinowski B, Brennan P, Ott M, Maynadie M, Benavente Y, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology. 2006;131:1879–86.
10. Maso LD, Franceschi S. Hepatitis C Virus and Risk of Lymphoma and Other Lymphoid Neoplasms : A Meta-analysis of Epidemiologic Studies. Cancer Epidemiology,Biomarkers & Prevention. 2006;15:2078–86.
11. Mathers CD, Boschi-pinto C, Lopez AD. Cancer incidence, mortality and survival by site for 14 regions of the world. Global Programme on Evidence for Health Policy Discussion Paper No. 13. 2001:2-47.
12. Ezzat S, Abdel-Hamid M, Eissa SA-L, Mokhtar N, Labib NA, El-Ghorory L, et al. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health. 2005;208:329–39.
13. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology. 2000;32:111–5.
14. Darwish MA, Faris R, Clemens JD, Rao MR, Edelman R. High seroprevalence of hepatitis A, B, C, and E viruses in residents in an Egyptian village in The Nile Delta: a pilot study. Am J Trop Med Hyg. 1996;54:554–8.
15. Michot J-M, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol. 2015;90:197–203.
16. Armitage JO. Staging Non-Hodgkin Lymphoma. CA Cancer J Clin. 2005;55:368–376.
17. Gouda I, Nada O, Ezzat S, Eldaly M, Loffredo C, Taylor C, et al. Immunohistochemical detection of hepatitis C virus (genotype 4) in B-cell NHL in an Egyptian population: correlation with serum HCV-RNA. Appl Immunohistochem Mol Morphol . 2010;18:29–34.
18. Farawela H, Khorshied M, Shaheen I, Gouda H, Nasef A, Abulata N. Infection , Genetics and Evolution The association between hepatitis C virus infection , genetic polymorphisms of oxidative stress genes and B-cell non-Hodgkin ’ s lymphoma risk in Egypt. Infect Genet Evol. 2012;12:1189–94.
19. Goldman L, Ezzat S, Mokhtar N, Abdel-Hamid A, Fowler N, Gouda I, et al. Viral and non-viral risk factors for non-Hodgkin’s lymphoma in Egypt: heterogeneity by histological and immunological subtypes. Cancer Causes Control. 2009;20:981–7.
20. Kadry DY, Khorshed AM, Rashed RA, Mokhtar NM. Association of Viral Infections with Risk of Human Lymphomas , Egypt. Asian Pacific Journal of Cancer Prevention. 2016;17:1705–12.
21. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008;6:451–8.
22. Couronne L, Bachy E, Roulland S, Nadel B, Davi F, Armand M, et al. From hepatitis C virus infection to B-cell lymphoma. Annals of Oncology. 2017;:1–9.
23. Khaled H, Abu-taleb F, Haggag R. Hepatitis C virus and non-Hodgkin ’ s lymphomas : A minireview. Journal of Advanced Research .2017;131–7.
24. El-hefni AM, Elgohary TA, Kotb A, Abu-taleb FM. Efficacy of Ribavirin to Prevent Hepatitis Reactivation in Hepatitis C Virus-Infected Patients Treated for Non-Hodgkin Lymphoma , Single Egyptian Center Study. J Hematol .2013;2:14–21.
25. Othman W, Salem DA, Abd El-Aziz SM, Arafa MM, Farag RE, Eletreby S. B-cell clonality and t(14;18) in Egyptian patients with chronic hepatitis C and its relation to antiviral therapy. Egypt J Haematol. 2013;38:90–5.
26. El-Fishawy H, Saadi G, Hassaballa M, Hussein M, Doss W, Ragab G, et al. Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective. J Adv Res. 2016;7:391–402.
27. Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S. B-cell non-Hodgkin’s lymphoma and hepatitis C virus infection: a systematic review. Int J cancer. 2004;111:1–8.
28. Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, et al. The effect of antiviral therapy on t ( 14 ; 18 ) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood.2001;97:1555–60.
29. Pozzato G, Mazzaro C, Maso LD, Mauro E, Zorat F, Moratelli G, et al. Hepatitis C virus and non-Hodgkin ’ s lymphomas : Meta- analysis of epidemiology data and therapy options. World J Hepatol . 2016;8:107–16.
30. Lim LY, La D, Cserti-gazdewich CM, Shah H, Hpte M. Lymphoma Remission by Interferon-Free HCV Eradication Without Chemotherapy. ACG Case Reports Journal. 2015;3:69–70.
31. Arcaini L, Besson C, Frigeni M, Visentini M, Torres HA, Loustaud-ratti V, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128:2527–33.